Table 8 Total treatment costs for with and without SEB scenarios in year 5
Patient type (CKD stage) | Treatments for anemia of CKD | Year 5 total costs ($) | |
|---|---|---|---|
Without SEB | With SEB | ||
Stage III/IV | Short acting ESA (SC) | 41,530,100 | 26,014,455 |
Llong acting ESA (SC) | 43,200,535 | 27,060,815 | |
Epoetin SEB | - | 18,505,171 | |
Stage V | Short acting ESA (SC) | 28,324,361 | 17,742,380 |
Long acting ESA (SC) | 19,614,295 | 12,286,394 | |
Short acting ESA (IV) | 116,364,164 | 72,890,512 | |
Long acting ESA (IV) | 80,917,865 | 50,686,950 | |
Epoetin SEB | - | 53,556,198 | |
Total | 329,951,320 | 278,742,875 | |